Kintor Pharmaceutical Receives Emergency Use Authorization for Proxalutamide for the Treatment of COVID-19 in Paraguay

SUZHOU, China, July 16, 2021 /PRNewswire/ -- Kintor Pharmaceutical Limited (HKEX:9939), a clinical-stage biotechnology company developing innovative small molecule and biological therapeutics, today announced that Paraguay's Ministry of Public Health and Social Welfare (MSPBS) has granted an emergency use authorization (EUA) for proxalutamide to treat hospitalized patients with COVID-19 infections at the MSPBS hospitals.

proxalutamide

The first hospital to use proxalutamide under the EUA, Hospital Barrio Obrero, part of Paraguay's MSPBS network, has reported promising initial results. Of the first 25 COVID-19 inpatients treated with Proxaluatmide, only 1 patient (4%) died. Such mortality rate was lower than the usual mortality rate of COVID-19 inpatients in Paraguay. In addition, proxalutamide has demonstrated potential benefits in 7 of the patients who initially required high flow oxygen.

Dr. Youzhi Tong, the founder, Chairman, and CEO of Kintor Pharmaceutical, commented, "We are delighted to see that proxalutamide is saving lives in Paraguay following the EUA from the MSPBS. We are actively exploring additional EUAs of proxalutamide in other countries and regions to help COVID-19 patients around the world."

About Proxalutamide (GT-0918)

Proxalutamide is a nonsteroidal antiandrogen — specifically, a selective high-affinity silent antagonist of the androgen receptor — under development for the potential treatment of COVID-19, prostate cancer, and breast cancer. Kintor Pharmaceutical received approval from the U.S. Food and Drug Administration(FDA) and the Brazilian Health Regulatory Agency (ANVISA) to conduct phase III clinical trials with proxalutamide in patients with COVID-19. The company is now conducting two registered phase III multi-regional clinical trials (MRCT) of proxalutamide for the treatment of COVID-19 outpatients, and one phase III MRCT for COVID-19 inpatients in countries and regions including the United StatesSouth America (including Brazil), the European Union, and Asia.

About Kintor Pharmaceutical Limited

Kintor Pharmaceutical Limited is developing and commercializing a robust pipeline of innovative small molecule and biological therapeutics for androgen-receptor-related disease areas with unmet medical needs, including COVID-19, prostate, breast and liver cancer, alopecia and acne. For more information, visit www.kintor.com.cn.

Source:https://www.prnewswire.com/news-releases/kintor-pharmaceutical-receives-emergency-use-authorization-for-proxalutamide-for-the-treatment-of-covid-19-in-paraguay-301335427.html

Company Code (Hong Kong Stock Exchange): HKG:9939

Update (Dec 2021): Kintor Pharma Provides Update on One of its Three Multi-Regional Phase 3 Trials of Proxalutamide for COVID-19

Comments

Labels

Show more

Popular posts from this blog

10 Best Natural Ozempic Alternatives 2024

Fenbendazole Joe Tippens Protocol: A Simple Step-by-Step Guide (2023)

Can Diet and Lifestyle influence your Risk of getting Cancer? Let the Science Speak (2024)

12 Natural Alternatives to Oral Ivermectin (2023) - Evidence based Review

Longevity and Anti Aging: One Day MD Guide and Review (2024 Edition)

Dr Peter McCullough Protocol: Hydroxychloroquine and Home Treatment for COVID-19 (2023)

10 Best Vitamin C Serums Recommended by Dermatologists 2024

Branch Chain Amino Acid Deficiency Linked to Autism?

9 Best Vitamin C Serums for Brighter Skin 2024

Quercetin and Zinc: Dr Zelenko Prevention and Treatment Protocol

Archive

Show more